Research & Development

Nuclera has announced that it has been awarded two grants from Innovate UK, totalling £1.14m.

The funding comprises of a £790,000 flexible, agile, scalable and sustainable technologies (FASST) grant awarded in collaboration with DeepMirror, and a £350,000 Engineering Biology grant.

The FASST grant makes up part of the Innovate UK Transforming Medicines Manufacturing (TMM) programme, and is in tended to support and grow the UK’s capabilities in medicines manufacturing through the development of first-of-a-kind technologies in order to accelerate patient access to new drugs and treatments.

Nuclera is one of 48 companies that have been given the Engineering Biology grant, intended to use engineering biology to combat various challenges within the health, environment, food production and sustainability industries. Dr Michael Chen, chief executive officer and co-founder at Nuclera, commented: “Receiving both grants from Innovate UK is testament to the power of eProtein Discovery and demonstrates that Nuclera has the technical innovation to address global unmet challenges in the fields of manufacturing and engineering biology. We look forward to working with DeepMirror, Dr Beis (via Imperial Consultants) and Dr Quigley from Diamond Light Source on both projects.”

Dr Andrew Quigley, group leader of Diamond’s Membrane Protein Lab (MPL), added: “Nuclera’s proposed platform aims to assess the most suitable conditions to obtain functional protein, and the MPL is well positioned to assist in this development with over 30 different membrane protein controls available.”